Pharmaceuticals
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
* Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Benefits in Previously Treated, CLDN18.2-positive Gastric Cancer * Arcotatug Tavatecan Demonstrated a Favorabl...
2026-10-23 20:00
3594
Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026
SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a trial-in-progress poster outlining the design of the ...
2026-10-23 19:00
3792
ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026
SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate in BIO-...
2026-10-23 10:07
2798
Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep
Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company
advances toward clinical development and attracts Chris Brearley, M.D., as
Chief Medical Officer
INDIANAPOLIS, Oct. 23, 2026 /PRNewswire/ -- Carnyx Therapeutics Ltd.
2026-10-23 08:30
2819
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from Ascletis - Pivotal trial designed to enroll approxima...
2026-10-23 08:10
3935
Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis
The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the disc...
2026-10-23 08:02
3050
ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026
SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011,will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress. These p...
2026-10-23 08:00
3092
Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration
Building on more than five decades in Hong Kong, Johnson & Johnson is committed to advancing better health through science, innovation and collaboration for patients and communities in Hong Kong. The partnership will help strengthen clinical research, develop future healthcare talent and su...
2026-10-22 23:52
4120
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
* GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. * Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, It...
2026-10-22 22:30
4089
ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow
The ZEISS CT LUCIA 621P monofocal intraocular lens (IOL) is added to the ZEISS Cataract Workflow in the Japanese market, supporting good visual outcomes for patients. JENA, Germany and TOKYO, Oct. 22, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today the commercial availability of th...
2026-10-22 21:00
2053
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26, 2026 (the "Share Consol...
2026-10-22 20:00
4479
Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa
SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtypes of Epidermolysis Bullosa MOUNT PLEASANT, S.C., Oct. 22, 2026 /PRNewswire/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmace...
2026-10-22 20:00
2019
HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
* Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity * Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational...
2026-10-22 18:00
2303
Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission
SEONGNAM, South Korea, Oct. 22, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)', its RNA...
2026-10-22 13:30
2368
Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization
Indegene is recognized for combining domain-led AI, knowledge orchestration,
and integrated execution to transform pharmaceutical commercialization
workflows.
SAN ANTONIO, Oct. 22, 2026 /PRNewswire/ -- Frost & Sullivan
2026-10-22 13:30
1924
Taimei Technology and GreenLight Clinical Expand Strategic Partnership at AusBiotech 2026 to Pioneer AI-Native Trial Execution Across Asia-Pacific
GOLD COAST, Australia, Oct. 22, 2026 /PRNewswire/ -- Taimei Technology, a global provider of AI-powered clinical development platforms, and GreenLight Clinical (GLC), a physician-led contract research organization (CRO), today announced an expanded strategic partnership at AusBiotech 2026. Evolvi...
2026-10-22 08:00
7282
Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids
DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced today that its THERAKOS™ CELLEX™ Photopheresis System has received certification under the EU MDR for an ...
2026-10-22 02:01
3245
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
* The study evaluates patients with liver cancer at high risk of recurrence following surgical resection * Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focus...
2026-10-21 21:10
4641
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
* Becomes the 7th International Registrational Clinical Trial for Ivonescimab * Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its ...
2026-10-21 20:42
2571
Axtria Wins 2026 Minsky Award for Excellence in AI for the Third Consecutive Year
AI-powered Next Best Action solution generated more than $180 million in
incremental revenue for a brand for a global pharmaceutical leader
BERKELEY HEIGHTS, N.J., Oct. 21, 2026 /PRNewswire/ -- Axtria Inc.
2026-10-21 20:15
2270
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59273
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
54297
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52334
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
21776
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
17092